Amphotericin B
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Amphotericin B: From Systemic Fungal Infections to Esophageal Candidiasis
One-Sentence Summary
Amphotericin B is a broad-spectrum polyene antifungal agent, long established as a gold-standard treatment for serious invasive systemic fungal infections. The TxGNN model predicts it may be effective for Esophageal Candidiasis, with 2 clinical trials and 19 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Systemic fungal infections (registered product details not available in current system) |
| Predicted New Indication | Esophageal Candidiasis |
| TxGNN Prediction Score | 0.00% |
| Evidence Level | L2 |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, Amphotericin B is a polyene macrolide antifungal whose efficacy in treating serious invasive fungal infections has been well established over several decades. It is known to bind with high affinity to ergosterol — a sterol unique to fungal cell membranes — forming transmembrane pores that disrupt osmotic equilibrium and cause leakage of intracellular contents, leading to direct fungicidal activity against Candida species. Both intravenous formulations — conventional deoxycholate (Fungizone) and liposomal (AmBisome) — can achieve effective drug concentrations at esophageal mucosal tissue.
Esophageal candidiasis is caused by Candida albicans and, less commonly, other Candida species (C. glabrata, C. tropicalis, C. krusei). Because the disease pathogen is the very same target as Amphotericin B’s mechanism of action, the mechanistic link is direct and well-established — this is not a leap across disease categories but an extension of proven antifungal activity to a specific anatomical site. The mucosal nature of esophageal disease is fully addressable by intravenous administration.
Clinically, Amphotericin B has long served as an alternative or salvage therapy for esophageal candidiasis, particularly in immunocompromised patients (HIV/AIDS, haematological malignancies) and in those with azole-refractory disease. A completed clinical trial (NCT00002041) directly evaluated Amphotericin B in biopsy-proven Candida esophagitis, and multiple randomised controlled trials have included AmB as an active comparator arm against newer agents such as caspofungin and anidulafungin — collectively confirming its established role in this indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002041 | Phase NA | Completed | N/A | Directly evaluated Amphotericin B for biopsy-proven Candida esophagitis in immunocompromised patients; assessed optimal treatment duration and compared two dose levels for efficacy and nephrotoxicity |
| NCT00041704 | Phase 2 | Completed | 19 | Phase 2 study of anidulafungin for azole-refractory mucosal candidiasis; Amphotericin B included as an alternative comparator, reflecting its salvage role in fluconazole-resistant esophageal disease |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8804799 | 1996 | RCT | Chemotherapy | Randomised trial of oral fluconazole vs IV Amphotericin B (0.3 mg/kg) in 31 cancer patients with endoscopy-confirmed esophageal candidiasis; both agents produced rapid resolution of dysphagia and odynophagia |
| 11796357 | 2002 | RCT | Antimicrobial Agents and Chemotherapy | Phase 2 randomised double-blind multicentre study comparing caspofungin vs Amphotericin B (0.5 mg/kg/day IV) for oropharyngeal and esophageal candidiasis; established AmB as the active comparator benchmark |
| 41226935 | 2025 | Clinical Pharmacotherapy Review | Journal of Clinical Medicine | Comprehensive review of pharmacological management of oral and esophageal candidiasis from a clinical pharmacotherapy perspective; positions Amphotericin B within current treatment algorithms |
| 10839593 | 2000 | Clinical Trial | AIDS | ACTG Study 295; evaluated Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in HIV-positive patients, demonstrating AmB’s utility in azole-resistant mucosal disease |
| 35699443 | 2022 | Animal/Preclinical | Antimicrobial Agents and Chemotherapy | Evaluated cochleated oral formulation of Amphotericin B in mucocutaneous candidiasis mouse models and azole-resistant CMC patients; supports feasibility of non-parenteral AmB for mucosal candidiasis |
| 7811544 | 1994 | Cohort/Resistance Review | AIDS Research and Human Retroviruses | Reviewed fluconazole-resistant mucosal candidiasis patterns in HIV patients; discusses Amphotericin B as a key salvage option for azole-resistant esophageal and oropharyngeal disease |
| 11590489 | 2000 | Review | HIV Clinical Trials | Reviewed therapeutic options for oropharyngeal and esophageal candidiasis in HIV/AIDS patients; contextualises Amphotericin B’s role relative to azoles and echinocandins |
| 10959741 | 2000 | Cohort Study | Pediatric Infectious Disease Journal | Investigated clinical presentation and risk factors of esophageal candidiasis in a large prospectively monitored cohort of HIV-infected children at the National Cancer Institute |
| 11363911 | 1996 | Review | Journal of the International Association of Physicians in AIDS Care | Overview of candidiasis — including esophageal involvement — in immunocompromised hosts; includes discussion of Amphotericin B therapy |
| 3181663 | 1983 | Original Article | Digestive Diseases and Sciences | Early clinical characterisation of Candida esophagitis including odynophagia, dysphagia, and GI bleeding; establishes antifungal treatment (including Amphotericin B) as standard of care |
Malaysia Market Information
The evidence pack confirms 2 registered products in Malaysia with market status 已上市 (Marketed). However, detailed registration data — including licence numbers, product names, dosage forms, and approved indication text — are not available in the current evidence pack. Please refer to the NPRA registration database for full product details.
Safety Considerations
Please refer to the package insert for safety information.
Note: Key warnings, contraindications, and drug interaction data were not retrievable in this evidence pack (Data Gap DG001 — Blocking severity). Remediation: download and parse the NPRA-approved package insert PDF. Known class-level concerns for Amphotericin B include infusion-related reactions and nephrotoxicity with the deoxycholate formulation; liposomal formulations carry a significantly improved tolerability profile.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Amphotericin B’s antifungal mechanism directly targets the causative pathogen of esophageal candidiasis (Candida spp. via ergosterol binding), making this a mechanistically sound application. A completed clinical trial has directly evaluated AmB in biopsy-confirmed Candida esophagitis, multiple published RCTs include AmB as the active comparator, and a 2025 clinical pharmacotherapy review positions it within current treatment guidelines — collectively meeting the L2 evidence threshold for a Proceed with Guardrails recommendation.
To proceed, the following is needed:
- Safety data retrieval (Blocking): Download and parse the NPRA package insert PDF to extract key warnings, contraindications, and drug interaction data (DG001)
- Mechanism of action data: Query the DrugBank API to obtain the full MOA profile for Amphotericin B (DG002)
- Registered dosage forms: Confirm which of the 2 registered Malaysian products is the deoxycholate vs. liposomal formulation, as these differ substantially in safety profile and dosing
- Safety monitoring protocol: Define nephrotoxicity monitoring plan (serum creatinine, electrolytes) and infusion-related reaction management, particularly for the conventional formulation
- Azole-resistance context: Clarify the local Malaysian epidemiology of fluconazole-resistant Candida to position AmB’s role relative to echinocandins as first-line alternatives in resistant cases
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.